Article Menu

Export Article

More by Authors Links

Article Data

  • Views 4339
  • Dowloads 183

Editorials

Open Access

Antiandrogen activity of drugs for COVID-19. The case of sabizabulin

  • Yuki Kotani1,2,3
  • Beatrice Righetti1
  • Mary Ann Belli1
  • Giovanni Landoni1,2,*,

1Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy

2School of Medicine, Vita-Salute San Raffaele University, 20132 Milan, Italy

3Department of Intensive Care Medicine, Kameda Medical Center, 296-8602 Kamogawa, Japan

DOI: 10.22514/sv.2023.027 Vol.19,Issue 3,May 2023 pp.1-3

Submitted: 13 August 2022 Accepted: 18 October 2022

Published: 08 May 2023

*Corresponding Author(s): Giovanni Landoni E-mail: landoni.giovanni@hsr.it

PDF (153.43 kB) View Full-text

Cite and Share

Yuki Kotani,Beatrice Righetti,Mary Ann Belli,Giovanni Landoni. Antiandrogen activity of drugs for COVID-19. The case of sabizabulin. Signa Vitae. 2023. 19(3);1-3.

URL:

https://www.signavitae.com/articles/10.22514/sv.2023.027

References

[1] COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. 2022. Available at: https://www. covid19treatmentguidelines.nih.gov/ (Accessed: 06 September 2022).

[2] Gordon M, Skolnick A, Barnette KG. Phase II study of oral sabizabulin for the treatment of SARS-CoV-2 in hospitalised patients at high-risk for ARDS. 2022. Available at: https://online.eccmid.org/media-4157-phase-ii-study-of-oral-sabizabulin-forthe-treatment-of-sars-cov-2-in-hospitalised-patient (Accessed: 28 July 2022).

[3] Barnette KG, Gordon MS, Rodriguez D, Bird TG, Skolnick A, Schnaus M, et al. Oral sabizabulin for high-risk, hospitalized adults with Covid-19: interim analysis. NEJM Evidence. 2022; 1: EVIDoa2200145.

[4] Lee TC, Murthy S, Del Corpo O, Senécal J, Butler-Laporte G, Sohani ZN, et al. Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2022; 28: 1203–1210.

[5] The WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group; Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021; 326: 499–518.

[6] Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181: 271–280.e8.

[7] Davey RA, Grossmann M. Androgen receptor structure, function and biology: from bench to bedside. Clinical Biochemist Reviews. 2016; 37: 3–15.

[8] Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Annals of Oncology. 2020; 31: 1040–1045.

[9] Lyon M, Li J, Cullen J, Milinovich A, Kattan M, Jehi L, et al. 5α-reductase inhibitors are associated with reduced risk of SARS-CoV-2 infection: a matched-pair, registry-based analysis. Journal of Urology. 2022; 207: 183–189.

[10] Zangrillo A, Morselli F, Biagioni E, Di Stella R, Coloretti I, Moizo E, et al. Sex-related mortality differences in young adult septic shock patients. Signa Vitae. 2022; 1–7.

[11] Ghandehari S, Matusov Y, Pepkowitz S, Stein D, Kaderi T, Narayanan D, et al. Progesterone in addition to standard of care vs. standard of care alone in the treatment of men hospitalized with moderate to severe COVID-19. Chest. 2021; 160: 74–84.

[12] Nicastri E, Marinangeli F, Pivetta E, Torri E, Reggiani F, Fiorentino G, et al. A phase 2 randomized, double-blinded, placebo-controlled, multicenter trial evaluating the efficacy and safety of raloxifene for patients with mild to moderate COVID-19. EClinicalMedicine. 2022; 48: 101450.

[13] Cadegiani FA, McCoy J, Gustavo Wambier C, Goren A. Early antiandrogen therapy with dutasteride reduces viral shedding, inflam-matory responses, and time-to-remission in males with COVID-19: a randomized, double-blind, placebo-controlled interventional trial (EAT-DUTA AndroCoV Trial—Biochemical). Cureus. 2021; 13: e13047.


Submission Turnaround Time

Top